T · 4506.T
Sumitomo Pharma Co., Ltd.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Osaka 541-0045
- Website
- sumitomo-pharma.com
Price · as of 2025-03-31
$1,509.50
Market cap 962.04B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $950.61 | -37.02% |
| Intrinsic Value(DCF) | $484.30 | -67.92% |
| Graham-Dodd Method(GD) | $227.03 | -84.96% |
| Graham Formula(GF) | $2,008.63 | +33.07% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $610.58 | $842.71 | $9,882.84 | $579.79 | $1,475.91 |
| 2012 | $630.60 | $854.86 | $0.00 | $480.29 | $18.70 |
| 2013 | $1,093.09 | $1,245.29 | $0.00 | $556.00 | $186.17 |
| 2014 | $999.06 | $1,254.88 | $0.00 | $782.49 | $961.07 |
| 2015 | $1,179.61 | $1,199.27 | $301.96 | $837.90 | $159.91 |
| 2016 | $1,459.48 | $1,152.75 | $124.95 | $970.86 | $1,016.75 |
| 2017 | $1,546.77 | $1,450.16 | $523.00 | $1,026.38 | $732.87 |
| 2018 | $2,169.86 | $1,963.14 | $2,413.29 | $1,272.86 | $2,818.08 |
| 2019 | $1,939.18 | $1,856.39 | $543.56 | $1,195.82 | $807.80 |
| 2020 | $1,402.99 | $1,682.95 | $1,010.47 | $925.29 | $1,344.19 |
| 2021 | $2,168.07 | $2,348.32 | $679.69 | $1,304.76 | $2,070.89 |
| 2022 | $996.07 | $1,794.47 | $332.45 | $1,328.79 | $2,322.52 |
| 2023 | $649.60 | $809.14 | $172.06 | $0.00 | $0.00 |
| 2024 | $342.00 | $136.80 | $0.00 | $0.00 | $26,465.39 |
| 2025 | $1,058.00 | $950.61 | $90.39 | $227.03 | $2,008.63 |
AI valuation
Our deep-learning model estimates Sumitomo Pharma Co., Ltd.'s (4506.T) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $950.61
- Current price
- $1,509.50
- AI upside
- -37.02%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$484.30
-67.92% upside
Graham-Dodd
$227.03
-84.96% upside
Graham Formula
$2,008.63
+33.07% upside
About Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
- CEO
- Toru Kimura
- Employees
- 4.98K
- Beta
- 0.45
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($484.30 ÷ $1,509.50) − 1 = -67.92% (DCF, example).